2016 ESMO Congress
Christian U. Blank, MD, PhD, on Melanoma: Initial Data From the OpACIN Trial (German Language Version) 
Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses in German study findings on neoadjuvant ipilimumab plus nivolumab in patients with palpable stage III melanoma. (Abstract LB...
Martin H. Schuler, MD, on Gastric and GEJ Adenocarcinoma: Results of the FAST Study (German Language Version)
Martin H. Schuler, MD, of the University Hospital Essen, discusses in German findings from this phase II trial of epirubicin, oxaliplatin, and capecitabine with or without the antibody IMAB362 as firs...
Katja Weisel, MD, on Multiple Myeloma: Results of the CASTOR Study (German Language Version)
Katja Weisel, MD, of the University of Tübingen, discusses in German study findings on daratumumab, bortezomib, and dexamethasone vs bortezomib and dexamethasone in patients with relapsed or refractor...
Martin Reck, MD, PhD, on NSCLC: Results of KEYNOTE-024 (German Language Version)
Martin Reck, MD, PhD, of the LungenClinic, discusses in German study findings on pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced non-small cell lung cancer with a PD-L1...
Judith Balmaña, MD, PhD, on Metastatic Breast Cancer: Study Results on Lurbinectedin (Spanish Language Version) 
Judith Balmaña, MD, PhD, of Vall d’Hebron University Hospital, discusses in Spanish the findings of a single-agent phase II trial on the antitumor activity of lurbinectedin in BRCA1/2-associated metas...
Luis G. Paz-Ares, MD, PhD, on NSCLC: Results From the LUX-Lung 7 Trial (Spanish Language Version)
Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses in Spanish overall survival data on afatinib vs gefitinib in patients with EGFR mutation–positive non–small cell lung ...
Paolo A. Ascierto, MD, on Metastatic Melanoma: Ipilimumab Study Results (Italian Language Version) 
Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori–Fondazione Pascale, discusses in Italian overall survival and safety results from a phase 3 trial of ipilimumab at 3 mg/kg vs 10 mg/kg in patien...
Giorgio V. Scagliotti, MD, PhD, on ALK-Rearranged NSCLC: Results From the ASCEND-5 Trial (Italian Language Version)
Giorgio V. Scagliotti, MD, PhD, of the University of Torino, discusses in Italian study findings on ceritinib vs chemotherapy in patients with advanced ALK-rearranged non–small cell lung cancer previo...
Teresa Calimeri, MD, PhD, on DLBCL: Findings on High-Dose Methotrexate (Italian Language Version)
Teresa Calimeri, MD, PhD, of San Raffaele Hospital, discusses in Italian high-dose methotrexate as a CNS prophylaxis, shown to significantly improve outcome in patients with high-risk diffuse large B-...
Philippe Rochigneux, MD, on Solid Tumors: Use of Chemotherapy Near End of Life (French Language Version) 
Philippe Rochigneux, MD, of the Paoli Calmettes Institute, Marseille Cancer Center, discusses in French his findings on the high rates of chemotherapy used at the end of life for metastatic solid canc...
Alain Ravaud, MD, PhD, on RCC: Results of the S-TRAC Trial (French Language Version)
Alain Ravaud, MD, PhD, of Bordeaux University Hospital, discusses in French phase III findings on sunitinib vs placebo as adjuvant treatment for high-risk renal cell carcinoma after nephrectomy. (Abst...
Fabrice Barlesi, MD, PhD, on NSCLC: Results From the OAK Trial (French Language Version)
Fabrice Barlesi, MD, PhD, of Aix Marseille University and Assistance Publique Hopitaux De Marseille, discusses in French phase III findings on a comparison of atezolizumab with docetaxel in patients w...
Derek J. Jonker, MD, on Colorectal Cancer: Results From the CCTG/AGITG CO.23 Trial
Derek J. Jonker, MD, of The Ottawa Hospital Cancer Centre, discusses phase III study findings on napabucasin vs placebo in patients with pretreated advanced colorectal cancer. (Abstract 454O)
Christopher J. Sweeney, MBBS, on Prostate Cancer: CHAARTED Trial Follow-up
Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how long-term study results showed no survival benefit in men with ogliometastatic prostate cancer. (Abstract 720PD)
Christopher J. Sweeney, MBBS, on Localized Prostate Cancer: Metastasis-Free Survival as a Surrogate for Overall Survival
Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how this early clinical endpoint will accelerate the development of new therapies for localized intermediate and high-risk ...
Mansoor Raza Mirza, MD, on Ovarian Cancer: Results From the ENGOT-OV16/NOVA Trial
Mansoor Raza Mirza, MD, of Rigshospitalet, Copenhagen University Hospital, discusses phase III study findings on maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recur...
Heinz-Josef Lenz, MD, on Colon Cancer: Sidedness and Treatment Update
Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, discusses the importance of tumor location, and its implications for treatment, in right-sided and le...
Susana N. Banerjee, MBBS, PhD, on Ovarian Cancer: Results of the CORAL Trial
Susana N. Banerjee, PhD, MBBS, of The Royal Marsden NHS Foundation Trust, discusses phase II findings on abiraterone in patients with recurrent epithelial ovarian cancer. (Abstract LBA33)
Alexander Eggermont, MD, PhD, on Melanoma: Results From the EORTC 18071 Trial
Alexander Eggermont, MD, PhD, of Gustave Roussy, discusses final overall survival findings on ipilimumab vs placebo after complete resection of stage III melanoma. (Abstract LBA2)
Fabrice Barlesi, MD, PhD, on NSCLC: Results From the OAK Trial
Fabrice Barlesi, MD, PhD, of Aix Marseille University and Assistance Publique Hopitaux De Marseille, discusses phase III findings on a comparison of atezolizumab with docetaxel in patients with advanc...
Christian U. Blank, MD, PhD, on Melanoma: Initial Data From the OpACIN Trial
Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses study findings on neoadjuvant ipilimumab plus nivolumab in patients with palpable stage III melanoma. (Abstract LBA39)
Martin Reck, MD, PhD, on NSCLC: Results of KEYNOTE-024
Martin Reck, MD, PhD, of the LungenClinic, discusses study findings on pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced non-small cell lung cancer with a PD-L1 tumor pro...
Ezra E.W. Cohen, MD, on Head and Neck Cancer: Results of the ACTIVE8 Trial
Ezra E.W. Cohen, MD, of the University of California, San Diego, discusses study findings on chemotherapy plus cetuximab in combination with motolimod immunotherapy in patients with recurrent or metas...
Sumanta K. Pal, MD, on Urothelial Cancer: Results From the CheckMate 275 Trial
Sumanta K. Pal, MD, of the City of Hope, discusses phase II findings on the efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer who have received prior treatment...
Alain Ravaud, MD, PhD, on RCC: Results of the S-TRAC Trial
Alain Ravaud, MD, PhD, of Bordeaux University Hospital, discusses phase III findings on sunitinib vs placebo as adjuvant treatment for high-risk renal cell carcinoma after nephrectomy. (Abstract LBA11...
Yung-Jue Bang, MD, PhD, on Gastric Cancer: Results From the GOLD Trial
Yung-Jue Bang, MD, PhD, of Seoul National University Hospital, discusses phase III study findings on olaparib and paclitaxel in patients with advanced gastric cancer who have progressed following firs...
Matthew J. Ellis, PhD, MB, BCh, on Breast Cancer: Results of the FALCON Trial
Matthew J. Ellis, PhD, MB, BCh, of the Baylor College of Medicine, discusses phase III study findings on fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced disease. (Abstract LBA...
Melanie Royce, MD, PhD, on Breast Cancer: Results From the BOLERO-4 Trial
Melanie Royce, MD, PhD, of the University of New Mexico, discusses phase II study findings on first-line everolimus plus letrozole in patients with ER+, HER2− advanced breast cancer. (Abstract 222O)
Sian A. Pugh, MBBS, on Colorectal Cancer: Long-Term Results of the FACS Trial
Sian A. Pugh, MBBS, of Southampton University Hospital, discusses 6 to 12-year findings on the scheduled use of the CEA tumor marker and CT follow-up to detect recurrence of colorectal cancer. (Abstra...
Sara A. Hurvitz, MD, on Breast Cancer: Results From the neoMONARCH Trial
Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses interim findings on abemaciclib in postmenopausal women with HR+/HER2- breast cancer. (Abstract LBA13)
Teresa Calimeri, MD, PhD, on DLBCL: Findings on High-Dose Methotrexate
Teresa Calimeri, MD, PhD, of San Raffaele Hospital, discusses high-dose methotrexate as a CNS prophylaxis, shown to significantly improve outcome in patients with high-risk diffuse large B-cell lympho...
Paolo A. Ascierto, MD, on Metastatic Melanoma: Ipilimumab Study Results
Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori–Fondazione Pascale, discusses overall survival and safety results from a phase III trial of ipilimumab at 3 mg/kg vs 10 mg/kg in patients with m...
Giorgio V. Scagliotti, MD, PhD, on ALK-Rearranged NSCLC: Results From the ASCEND-5 Trial
Giorgio V. Scagliotti, MD, PhD, of the University of Torino, discusses study findings on ceritinib vs chemotherapy in patients with advanced ALK-rearranged non-small cell lung cancer previously treate...
Luis G. Paz-Ares, MD, PhD, on NSCLC: Results From the LUX-Lung 7 Trial 126
Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses overall survival data on afatinib vs gefitinib in patients with EGFR mutation-positive non-small cell lung cancer. (Ab...
Toni K. Choueiri, MD, on Metastatic RCC: Results From the ALLIANCE A031203 Trial
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on cabozantinib vs sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor a...
Martin H. Schuler, MD, on Gastric and Gastroesophageal Junction Adenocarcinoma: Results of the FAST Study
Martin H. Schuler, MD, of the University Hospital Essen, discusses findings from this phase II trial of epirubicin, oxaliplatin, and capecitabine with or without the antibody IMAB362 as first-line th...
Katja Weisel, MD, on Multiple Myeloma: Results of the CASTOR Study
Katja Weisel, MD, of the University of Tübingen, discusses study findings on daratumumab, bortezomib, and dexamethasone vs bortezomib and dexamethasone in patients with relapsed or refractory multiple...
Philippe Rochigneux, MD, on Solid Tumors: Use of Chemotherapy Near the End of Life
Philippe Rochigneux, MD, of the Paoli Calmettes Institute, Marseille Cancer Center, discusses his findings on the high rates of chemotherapy used at the end of life for metastatic solid cancer, especi...
Judith Balmaña, MD, PhD, on Metastatic Breast Cancer: Study Results on Lurbinectedin
Judith Balmaña, MD, PhD, of Vall d’Hebron University Hospital, discusses the findings of a single-agent phase II trial on the antitumor activity of lurbinectedin in BRCA1/2-associated metastatic breas...
Janessa J. Laskin, MD, on Tumor Gene Expression and Advanced Cancers
Janessa J. Laskin, MD, of the British Columbia Cancer Agency, discusses the ways in which availability of tumor gene expression data facilitates clinical decision-making for patients with advanced can...
Arjun V. Balar, MD, on Urothelial Cancer: Results From KEYNOTE-052
Arjun V. Balar, MD, of the NYU Perlmutter Cancer Center, discusses preliminary phase II study findings on pembrolizumab as first-line therapy for advanced/unresectable or metastatic urothelial cancer....
Omid Hamid, MD, on Melanoma: Results From the KEYNOTE-002 Study
Omid Hamid, MD, of The Angeles Clinic and Research Institute, discusses survival data from this clinical trial on pembrolizumab vs investigator-choice chemotherapy for ipilimumab-refractory melanoma. ...
Shou-Ching Tang, MD, PhD, on Recurrent CNS Metastases in Breast Cancer: Study Results on a Novel Conjugate
Shou-Ching Tang, MD, PhD, of the Georgia Cancer Center, discusses findings on a novel peptide–paclitaxel conjugate that crosses the blood-brain barrier and shows activity in breast cancer patients wit...
Tony Mok, MD, on NSCLC: Results of the IMPRESS Study
Tony Mok, MD, of The Chinese University of Hong Kong, discusses the final overall survival analysis from this trial on gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive non-small cell l...
Jung-min Lee, MD, on Ovarian Cancer: Study Results on Checkpoint Kinase Inhibitors
Jung-min Lee, MD, of the National Cancer Institute, discusses findings of a phase II study of the cell cycle checkpoint kinase inhibitors LY2606368 and prexasertib monomesylate monohydrate in sporadic...
